KPV

KPV is a tripeptide derived from the C-terminal of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13), studied in anti-inflammatory and gut-barrier research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.

Potential anti-inflammatory signaling via melanocortin pathways.

KPV is a three-amino-acid peptide (lysine-proline-valine) derived from the C-terminus of alpha-MSH. It is primarily discussed in the research community for its anti-inflammatory properties and its role in gut barrier function, particularly in models of inflammatory bowel disease (IBD). One of the unique aspects of KPV is its ability to be administered orally, which is uncommon for most peptides that typically degrade in the digestive tract. KPV's proline and valine residues provide resistance to gut enzymes, and its small size allows it to be absorbed through a transporter known as PepT1. This transporter is particularly concentrated in inflamed intestinal tissue, making oral KPV potentially effective in targeting the areas of interest in gut-focused research.

In addition to oral administration, KPV can also be used subcutaneously, topically, and, less commonly, intranasally. The choice of administration route often depends on the specific research target. For systemic anti-inflammatory models, subcutaneous administration is preferred, while topical formulations are sometimes used for localized skin inflammation. The dosing range for KPV is typically between 200-500 mcg daily, although no completed human dose-finding trial has defined an official dose. The dosing schedules are derived from preclinical studies and community-derived planning notes.

KPV's mechanism of action is distinct from other melanocortin-type peptides, as it does not trigger pigmentation and does not engage melanocortin-receptor signaling. Instead, KPV has been shown to reduce colitis severity in animal models, as evidenced by studies such as Dalmasso et al. (2008) in Gastroenterology, which identified PepT1-mediated uptake as a central mechanism. Other studies, like Xiao et al. (2017) in Molecular Therapy, demonstrated that nanoparticle-delivered KPV improved targeting to inflamed colonic tissue and reduced inflammatory markers. Overall, KPV's anti-inflammatory effects are attributed to its ability to modulate specific inflammatory pathways, particularly through the inhibition of NF-kB signaling, without broadly suppressing the immune system, as noted in animal studies. [Source: Peptide Dosing Protocols]

Amino sequence: Lys-Pro-Val (KPV)

COA: View certificate (batch TET-4893-A) →

Teton Labs product catalog · research-use compound data.